EP3674303B1 - Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant - Google Patents

Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant Download PDF

Info

Publication number
EP3674303B1
EP3674303B1 EP18848270.7A EP18848270A EP3674303B1 EP 3674303 B1 EP3674303 B1 EP 3674303B1 EP 18848270 A EP18848270 A EP 18848270A EP 3674303 B1 EP3674303 B1 EP 3674303B1
Authority
EP
European Patent Office
Prior art keywords
amino
pyrimidine
phenyl
ene
trifluoroethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP18848270.7A
Other languages
German (de)
English (en)
Other versions
EP3674303A1 (fr
EP3674303A4 (fr
Inventor
Jin Hee Ahn
Hail Kim
Jaemyoung Suh
In-Kyu Lee
Kwang-Eun Kim
Kun-Young Park
Eun Jung Bae
Ko Eun SHONG
Suvarna Haus-Habhau PAGIRE
Ajin LIM
Jae-Han Jeon
Haushabhau Shivaji Pagire
Haiying Zhang
Myung-Hwa Kim
Jung-In PYO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Advanced Institute of Science and Technology KAIST
Gwangju Institute of Science and Technology
Industry Academic Cooperation Foundation of KNU
Curacle Co Ltd
Original Assignee
Korea Advanced Institute of Science and Technology KAIST
Gwangju Institute of Science and Technology
Industry Academic Cooperation Foundation of KNU
Curacle Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Advanced Institute of Science and Technology KAIST, Gwangju Institute of Science and Technology, Industry Academic Cooperation Foundation of KNU, Curacle Co Ltd filed Critical Korea Advanced Institute of Science and Technology KAIST
Publication of EP3674303A1 publication Critical patent/EP3674303A1/fr
Publication of EP3674303A4 publication Critical patent/EP3674303A4/fr
Application granted granted Critical
Publication of EP3674303B1 publication Critical patent/EP3674303B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition comprising the same.
  • Obesity means a condition of excessive accumulation of fat tissue in the body. Obesity is caused by excessive intake of nutrients relative to energy consumption over a long period of time. In modern society, obesity has been classified as a disease since 2013 due to westernization of diet, excessive food intake and lack of exercise. The number of obese patients has increased steadily every year, and more than 500 million adults in the world were found to be obese in 2014. In addition, obesity causes diseases such as type 2 diabetes, fatty liver, circulatory disease, high blood pressure, stroke, colorectal cancer, breast cancer, ovarian cancer and the like.
  • Treatment methods for obesity include diet, exercise, drug treatment and surgical operation.
  • the drug can be classified into an obesity agent acting on the central nerve and an obesity agent acting on the peripheral nerve.
  • the conventional anti-obesity agents are the therapeutic agents that suppress appetite by inhibiting serotonin present in the central nervous system.
  • the serotonin present in the central nervous system affects mood, sleep and memory in addition to appetite.
  • the conventional anti-obesity drugs acting on the central nervous system have been reported side effects such as headache, nervousness, tension and depression.
  • serotonin is a monoamine that acts on the central and peripheral nervous systems. Serotonin does not pass through the blood brain barrier, and is synthesized in the central and peripheral nervous systems, respectively. In the peripheral nervous system, serotonin plays an important role in controlling metabolism of the peripheral tissue. Specifically, if serotonin is over-secreted in the peripheral tissue, it hinders the activity of brown fat cells that burn energy ( Oh C et al., Nature Communication 6, 6794, 2015 ). Thus, it is possible to activate the metabolism of the peripheral tissue by inhibiting the synthesis of the serotonin present in the peripheral nervous system.
  • the following diseases are known as serotonin-related diseases.
  • serotonin acts as a tumor growth factor and is associated with various cancers ( Ann Med 2000; 32: 187-194 .). Particularly, studies have been reported that serotonin is directly involved in human breast cancer, and cancer progression can be prevented by suppressing the synthesis of serotonin by down-regulation TPH1 in tumor cells since the increase of serotonin can cause malignant progression of breast cancer cells ( Breast Cancer Research 2009, 11:R81 ). Furthermore, it is known that serotonin promotes the growth and survival of tumor cells in hepatocellular carcinoma ( HEPATOLOGY 2010; 51:1244-1254 .).
  • Serotonin is released from platelets and affects the human circulatory system. It is known that the increase of serotonin can cause circulatory diseases such as neointimal hyperplasia, carcinoid tumor, valve thrombosis, ventricular fibrosis, ventricular hypertrophy, arrhythmia, coronary artery spasm, increased occlusion pressure and increased blood pressure ( Archives of Circulatory Disease (2017) 110, 51-59 ). Particularly, carcinoid tumor (carcinoid syndrome) is a disease characterized by the occurrence of watery diarrhea, temporary flushing, bronchial contraction, and eventually causing right valve heart disease. Symptoms of carcinoid syndrome are caused by the elevated level of serotonin secreted by some tumors.
  • Serotonin plays a particularly important role in the onset of carcinoid-related diarrhea and is also known to be associated with the development of carcinoid heart disease.
  • telotristat etiprate a well-known TPH inhibitor
  • telotristat etiprate a well-known TPH inhibitor
  • TPH1 tryptophan hydroxylase 1
  • serotonin is synthesized when tryptophan is hydroxylated by tryptophan hydroxylase. Then, serotonin is produced when the hydroxylated tryptophan is decarboxylated. Therefore, the synthesis of serotonin can be suppressed by inhibiting tryptophan hydroxylase.
  • Tryptophan hydroxylase has two subtypes: tryptophan hydroxylase 1 (TPH1) and tryptophan hydroxylase 2 (TPH2).
  • TPH1 is mainly expressed in the peripheral tissues including the pineal gland.
  • TPH2 is expressed in the brain and the intestinal nervous system.
  • Inhibition of tryptophan hydroxylase can be a therapeutic target for various cancers, circulatory and digestive system diseases associated with the changes in serotonin as described above.
  • It is another object of the present invention to provide a pharmaceutical composition comprising the novel tryptophan hydroxylase inhibitor as an active ingredient for the prevention or treatment of metabolic disorder.
  • It is another object of the present invention to provide a pharmaceutical composition comprising the novel tryptophan hydroxylase inhibitor as an active ingredient for the prevention or treatment of cancer.
  • It is another object of the present invention to provide a pharmaceutical composition comprising the novel tryptophan hydroxylase inhibitor as an active ingredient for the prevention or treatment of digestive or circulatory system disorders.
  • the present invention provides a compound represented by formula 1 below, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof: wherein,
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of metabolic disorder.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of digestive or circulatory system disorders.
  • the present invention provides a health functional food comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or amelioration of metabolic disorder, cancer, digestive or circulatory system disorders.
  • the present invention provides a method for preventing or treating metabolic disorder, cancer, digestive or circulatory system disorders, which comprises the step of administering a pharmaceutical composition or a health functional food comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
  • the present invention provides a use of the pharmaceutical composition or the health functional food comprising a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating metabolic disorder, cancer, digestive or circulatory system disorders.
  • the novel tryptophan hydroxylase inhibitor of the present invention has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorder, cancer, digestive or circulatory system disorders, related to TPH1 activity.
  • the novel tryptophan hydroxylase inhibitor of the present invention has an excellent treatment effect on inflammatory bowel disorder, and thus can be usefully used for the treatment of inflammatory bowel disorder.
  • Alkyl is a hydrocarbon having primary, secondary or tertiary carbon atoms.
  • an alkyl group can contain 1 to 20 carbon atoms (i.e., C 1-20 alkyl), 1 to 10 carbon atoms (i.e., C 1-10 alkyl), or 1 to 6 carbon atoms (i.e., C 1-6 alkyl).
  • alkyl group examples include methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2
  • Alkylene means a branched, straight or cyclic saturated hydrocarbon radical having two monovalent radical centers induced by the removal of two hydrogen atoms from the same or different two carbon atoms of the parent alkane.
  • an alkylene group can contain 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • the typical alkylene radical includes methylene (-CH 2 -), 1,1-ethyl (-CH(CH 3 )-), 1,2-ethyl (-CH 2 CH 2 -), 1,1-propyl (-CH(CH 2 CH 3 )-), 1,2-propyl (-CH 2 CH(CH 3 )-), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like, but not always limited thereto.
  • Alkenyl is a hydrocarbon having normal, secondary, tertiary or cyclic carbon atoms with one or more unsaturated regions, i.e. carbon-carbon and sp2 double bonds.
  • an alkenyl group can contain 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 12 carbon atoms (i.e., C 2-12 alkenyl), or 2 to 6 carbon atoms (i.e., C 2-6 alkenyl).
  • Alkenylene means a branched, straight or cyclic unsaturated hydrocarbon radical having two monovalent radical centers induced by the removal of two hydrogen atoms from the same or different two carbon atoms of the parent alkene.
  • an alkenylene group can contain up to 20 carbon atoms, up to 10 carbon atoms or up to 6 carbon atoms.
  • Alkoxy means a group having the chemical formula -O-alkyl, wherein the alkyl group defined above is attached to the parent compound through an oxygen atom.
  • the alkyl portion of the alkoxy group can contain 1 to 20 carbon atoms (i.e., C 1-20 alkoxy), 1 to 12 carbon atoms (i.e., C 1-12 alkoxy), or 1 to 6 carbon atoms (i.e., C 1-6 alkoxy).
  • suitable alkoxy group include methoxy (-O-CH 3 or -OMe), ethoxy (-OCH 2 CH 3 or-OEt), t-butoxy (-O-C(CH 3 ) 3 or -O-tBu), etc., but not always limited thereto.
  • Haloalkyl is an alkyl group wherein one or more hydrogen atoms of the alkyl group defined above are substituted with halogen atoms.
  • the alkyl portion of the haloalkyl group can contain 1 to 20 carbon atoms (i.e., C 1-20 haloalkyl), 1 to 12 carbon atoms (i.e., C 1-12 haloalkyl), or 1 to 6 carbon atoms (i.e., C 1-6 haloalkyl).
  • suitable haloalkyl group include -CF 3 , -CHF 2 , -CFH 2 , -CH 2 CF 3 , etc., but not always limited thereto.
  • Amino refers to -NR 2 , wherein “R” is independently selected from H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, etc.
  • R is independently selected from H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, etc.
  • alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl and substituted arylalkyl are as defined and described above.
  • the typical amino group includes -NH 2 , -N(CH 3 ) 2 , -NH(CH 3 ),-N(CH 2 CH 3 ) 2 , -NH(CH 2 CH 3 ), -NH (substituted or nonsubstituted benzyl), -NH (substituted or nonsubstituted phenyl), etc., but not always limited thereto.
  • Cycloalkyl refers to a saturated monocycle or poly-cycle containing only carbon atoms in the ring. Cycloalkyl can have 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle cycloalkyl and up to about 20 carbon atoms as a poly-cycle.
  • the monocyclic cycloalkyl contains 3 to 6 ring atoms, and more typically 5 or 6 ring atoms.
  • the bicyclic cycloalkyl contains 7 to 12 ring atoms arranged in [4,5], [5,5], [5,6] or [6,6] system, or 9 to 10 ring atoms arranged in [5,6] or [6,6] system or spiro-bonded ring.
  • Non-restrictive examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl (They can be substituted or nonsubstituted, respectively.
  • Aryl means an aromatic hydrocarbon radical induced by the removal of one hydrogen atom from six carbon atoms of the parent aromatic ring system.
  • an aryl group can contain 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms.
  • the typical aryl group includes radicals derived from benzene (for example, phenyl), substituted benzene, substituted or nonsubstituted naphthalene, substituted or nonsubstituted anthracene, substituted or nonsubstituted biphenyl, etc., but not always limited thereto.
  • Arylalkyl means a non-cyclic alkyl radical in which one hydrogen atom bound to a carbon atom, typically a terminal or sp3 carbon atom, is substituted with an aryl radical.
  • the typical arylalkyl group includes benzyl, 2-phenylethane-1-yl, naphthylmethyl, 2-naphthylethane-1-yl, naphthobenzyl, 2-naphthophenylethane-1-yl, etc., but not always limited thereto.
  • An arylalkyl group can contain 7 to 20 carbon atoms, for example an alkyl moiety can contain 1 to 6 carbon atoms and an aryl moiety can contain 6 to 14 carbon atoms.
  • substituted with respect to alkyl, alkylene, aryl, arylalkyl, heterocyclyl and the like, for example, “substituted alkyl”, “substituted alkylene”, “substituted aryl”, “substituted arylalkyl”, “substituted” heterocyclyl and “substituted carbocyclyl (for example, substituted cycloalkyl)" are each alkyl, alkylene, aryl, arylalkyl, heterocyclyl and carbocyclyl (for example, cycloalkyl) in which one or more hydrogen atoms are independently substituted with a non-hydrogen substituent.
  • Heterocycle or “heterocyclyl” used herein includes those described in the literatures [ Paquette, Leo A; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly, Chapters 1, 3, 4, 6, 7 and 9 ; The Chemistry of Heterocyclic Compounds, A Series of Monographs” (John Wiley & Sons, New York, 1950 to present), specifically, Volumes 13, 14, 16, 19 and 28 ; and J. Am. Chem. Soc. (1960) 82:5566 ], but not always limited thereto.
  • heterocycle includes “carbocycle” in which one or more (for example, 1, 2, 3 or 4) carbon atoms are substituted with a hetero atom (for example, O, N or S) as defined herein.
  • Heterocycle or “heterocyclyl” includes saturated rings, partially unsaturated rings, and aromatic rings (i.e., heteroaromatic rings).
  • Substituted heterocycle includes a heterocyclic ring substituted with any substituents disclosed herein, including, for example, a carbonyl group.
  • heterocycle examples include pyridyl, dihydropyridyl, tetrahydropyri (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxide tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinoliny
  • carbon-bound heterocycle can be bound to position 2, 3, 4, 5 or 6 of pyrazine, position 3, 4, 5 or 6 of pyridazine, position 2, 4, 5 or 6 of pyrimidine, position 2, 3, 5 or 6 of pyrazine, position 2, 3, 4 or 5 of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, 2, 4 or 5 position of oxazole, imidazole or thiazole, position 3, 4 or 5 of isoxazole, pyrazole or isothiazole, position 2 or 3 of aziridine, position 2, 3 or 4 of azetidine, position 2, 3, 4, 5, 6, 7 or 8 of quinoline, or position 1, 3, 4, 5, 6, 7 or 8 of isoquinoline, but not always limited thereto.
  • the carbon-bound heterocycle includes 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl (Each of them can be substituted or nonsubstituted.).
  • nitrogen-bound heterocycle can be bound to position 1 of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline and 1H-indazole, position 2 of isoindole or isoindolin, position 4 of morpholine, and position 9 of carbazole or ⁇ -carboline (Each of them can be substituted or nonsubstituted.), but not always limited thereto.
  • the nitrogen-bound heterocycle includes 1-aziridinyl, 1-azetidyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl and 1-piperidinyl (Each of them can be substituted or nonsubstituted.).
  • Heterocyclyl alkyl refers to a non-cyclic alkyl radical in which one of the hydrogen atoms bound to a carbon atom, typically a terminal or sp3 carbon atom, is substituted with a heterocyclyl radical (i.e., heterocyclyl-alkylene-residue).
  • the typical heterocyclyl alkyl group includes heterocyclyl-CH 2 -, 2-(heterocyclyl)ethane-1-yl, etc., but not always limited thereto.
  • the "heterocyclyl” moiety includes any of the heterocyclyl groups described above, including those described in the literature [Principles of Modern Heterocyclic Chemistry].
  • heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by carbon-carbon bonds or carbon-hetero atom bonds as long as the resulting group is chemically stable.
  • a heterocyclyl alkyl group can contain 2 to 20 carbon atoms, for example an alkyl moiety can contain 1 to 6 carbon atoms and a heterocyclyl moiety can contain 1 to 14 carbon atoms.
  • heterocyclyl alkyl examples include heterocycles containing 5-membered sulfur, oxygen and/or nitrogen such as thiazolylmethyl, 2-thiazolylethane-1-yl, imidazolylmethyl, oxazolylmethyl and thiadiazolylmethyl, etc., and heterocycles containing 6-membered sulfur, oxygen and/or nitrogen such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyrizinylmethyl, pyrimidylmethyl and pyrazinylmethyl, etc.
  • the heterocyclyl alkyl can be substituted or nonsubstituted.), but not always limited thereto.
  • Heteroaryl refers to an aromatic heterocyclyl having one or more hetero atoms in the ring.
  • Non-restricted examples of the suitable hetero atom that can be included in the aromatic ring include oxygen, sulfur and nitrogen.
  • Non-restricted examples of the heteroaryl ring include everything listed in the definition of "heterocyclyl,” including pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, furinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc (They can be substituted or nonsubstituted.).
  • Carbocycle or “carbocyclyl” means a saturated ring, partially unsaturated ring or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
  • the monocyclic carbocycle contains 3 to 6 ring atoms, and more typically 5 or 6 ring atoms.
  • the bicyclic carbocycle contains 7 to 12 ring atoms arranged in [4,5], [5,5], [5,6] or [6,6] system, or 9 to 10 ring atoms arranged in [5,6] or [6,6] system.
  • Examples of the monocyclic or bicyclic carbocycle include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl and naphthyl (They can be substituted or nonsubstituted, respectively.).
  • Optionally substituted refers to a specific portion of a compound of formula 1 having one, two, or more substituents (for example, an optionally substituted aryl group).
  • a “salt thereof” means any acid addition salt and/or base addition salt of the compound according to the present invention, preferably a pharmaceutically acceptable salt thereof.
  • the "pharmaceutically acceptable salt” means a salt of a compound and is suitable for use in contact with the tissues of humans or lower animals without excessive toxicity, irritation or allergic reactions within the scope of sound medical judgment, A compound having a reasonable gain/risk ratio balance, generally soluble or dispersible in water or oil, and effective for the intended use.
  • the pharmaceutically acceptable salt has a reasonable benefit/risk ratio balance, is generally soluble or dispersible in water or oil, and is effective for the intended use.
  • the term "isomer” is used to mean the stereoisomer commonly used by those skilled in the art without limitation.
  • the stereoisomer collectively refers to the isomer generated by changing the spatial arrangement of atoms in a molecule.
  • Examples of the stereoisomer include an enantiomer and a diastereomer, but not always limited thereto. Definitions of the enantiomer and diastereomer are apparent to those skilled in the art.
  • the enantiomer refers to an isomer that does not overlap with the mirror image, such as the relationship between the right hand and the left hand, and is also called an optical isomer.
  • the diastereomer is a generic term for stereoisomers that are not enantiomeric.
  • Diastereomer can be divided into the diastereomers with different spatial arrangements of the constituent atoms and the cis-trans isomers with different spatial arrangements of atoms due to the unfree rotation of carbon-carbon bonds in cycloalkaine and alkene compounds.
  • the present invention provides a compound represented by formula 1 below, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof: wherein,
  • R 1 is hydrogen or C 1-6 alkyl
  • R 1 is hydrogen or C 1-5 alkyl
  • R 1 can be hydrogen, methyl, ethyl, n-butyl, t-butyl, i-butyl, n-pentyl, t-pentyl, i-pentyl or neopentyl.
  • R 6 is hydrogen or tert-butoxycarbonyl.
  • R 3 can be
  • R 4 can be hydrogen, or
  • Examples of the compound represented by formula 1 according to the present invention include the following compounds:
  • the compound represented by formula 1 above can be a compound represented by formula 2 below.
  • Examples of the compound represented by formula 2 according to the present invention include the following compounds:
  • the compound represented by formula 1 or formula 2 can be an L-type or D-type optical isomer.
  • the compound can be an L type optical isomer.
  • the compound represented by formula 1 of the present invention can be used as a form of a pharmaceutically acceptable salt, in which the salt is preferably acid addition salt formed by pharmaceutically acceptable free acids.
  • the acid addition salt herein can be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, and phosphorous acid; non-toxic organic acids such as aliphatic mono/dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate, alkandioate, aromatic acids, and aliphatic/aromatic sulfonic acids; or organic acids such as acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, and fumaric acid.
  • inorganic acids such as hydrochloric acid, nitric
  • the pharmaceutically non-toxic salts are exemplified by sulfate, pyrosulfate, bisulfate, sulphite, bisulphite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutylate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, cabacate, fumarate, maliate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, tolu
  • the acid addition salt in this invention can be prepared by the conventional method known to those in the art.
  • the derivative represented by formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, dichloromethane, and acetonitrile, to which organic acid or inorganic acid is added to induce precipitation.
  • the precipitate is filtered and dried to give the salt.
  • the solvent and the excessive acid are distillated under reduced pressure, and dried to give the salt.
  • the precipitate is crystallized in an organic solvent to give the same.
  • a pharmaceutically acceptable metal salt can be prepared by using a base.
  • Alkali metal or alkali earth metal salt is obtained by the following processes: dissolving the compound in excessive alkali metal hydroxide or alkali earth metal hydroxide solution; filtering non-soluble compound salt; evaporating the remaining solution and drying thereof.
  • the metal salt is preferably prepared in the pharmaceutically suitable form of sodium, potassium, or calcium salt.
  • the corresponding silver salt is prepared by the reaction of alkali metal or alkali earth metal salt with proper silver salt (ex; silver nitrate) .
  • the present invention includes not only the compound represented by formula 1 and the pharmaceutically acceptable salt thereof, but also solvates, optical isomers, hydrates, and the like that can be prepared therefrom.
  • hydrate refers to a compound of the present invention or a salt thereof comprising a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular force.
  • the hydrate of the compound represented by formula 1 of the present invention can include a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular force.
  • the hydrate can contain 1 equivalent or more, preferably 1 to 5 equivalents of water.
  • Such hydrates can be prepared by crystallizing the compound represented by formula 1 of the present invention, the optical isomer thereof or the pharmaceutically acceptable salt thereof from water or a solvent containing water.
  • solvate refers to a compound of the present invention or a salt thereof comprising a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular force.
  • the preferred solvent include volatile, non-toxic, and/or suitable solvents for human administration.
  • isomers include tautomers, R or S isomers having asymmetric carbon centers, stereoisomers such as geometric isomers (trans and cis), and optical isomers (enantiomers).
  • the compound represented by formula 1 or 2 can be prepared according to the preparation methods shown in reaction formulas 1 to 5 below, or can be prepared by the preparation methods of the following examples.
  • reaction formulas 1 to 5 can be performed according to the conditions in the reaction formulas, but not always limited thereto.
  • the conditions can be used without limitation as long as they can derive the compound of the next step.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of metabolic disorder.
  • the metabolic disorder can be any one selected from the group consisting of obesity, diabetes mellitus, hyperlipidemia, arteriosclerosis, fatty liver, (nonalcoholic) fatty liver cirrhosis, (nonalcoholic) steatohepatitis, liver cirrhosis, celiac disease and hypertension.
  • composition can further comprise a pharmaceutically acceptable carrier, an additive or an excipient.
  • the compound represented by formula 1 can inhibit tryptophan hydroxylase.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer.
  • the cancer can be any one selected from the group consisting of colorectal cancer, breast cancer, ovarian cancer, carcinoid tumor and hepatocellular carcinoma.
  • composition can further comprise a pharmaceutically acceptable carrier, an additive or an excipient.
  • the compound represented by formula 1 can inhibit tryptophan hydroxylase.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of digestive or circulatory system disorder.
  • the digestive or circulatory system disorder can be any one selected from the group consisting of hepatitis, enteritis, colitis, ulcerative enteritis, Crohn's disease, pheochromocytoma, irritable bowel syndrome, gastrointestinal bleeding, peptic ulcer, gastritis, inflammatory bowel disorder, pulmonary syndrome and pulmonary hypertension.
  • composition can further comprise a pharmaceutically acceptable carrier, an additive or an excipient.
  • the compound represented by formula 1 can inhibit tryptophan hydroxylase.
  • the novel tryptophan hydroxylase inhibitor Since the compound represented by formula 1 of the present invention, the novel tryptophan hydroxylase inhibitor, has an excellent inhibitory effect on TPH1 (Experimental Example 2), it can be effectively used for the prevention or treatment of metabolic disorders, cancers, and digestive or circulatory system disorders, which are the diseases related to TPH1 activity. In particular, since the compound has an excellent therapeutic effect on inflammatory bowel disorder (Experimental Example 3), it can be effectively used for the treatment of inflammatory bowel disorder.
  • the inflammatory bowel disorder can be any one selected from the group consisting of enteritis, colitis, ulcerative enteritis, Crohn's disease, pheochromocytoma, irritable bowel syndrome, gastrointestinal bleeding, peptic ulcer and gastritis.
  • the compound represented by formula 1 or the pharmaceutically acceptable salt thereof can be administered orally or parenterally and be used in general forms of pharmaceutical formulation. That is, the compound represented by formula 1 or the pharmaceutically acceptable salt thereof can be prepared for oral or parenteral administration by mixing with generally used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.
  • Solid formulations for oral administration are tablets, pills, powders, granules and capsules. These solid formulations are prepared by mixing one or more compounds with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc.
  • Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions and emulsions.
  • Water insoluble excipients and suspensions can contain, in addition to the active compound or compounds, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc.
  • the pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient can be administered parenterally and the parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection.
  • the compound represented by formula 1 or the pharmaceutically acceptable salt thereof is mixed with a stabilizer or a buffering agent to produce a solution or a suspension, which is then formulated as ampoules or vials.
  • the composition herein can be sterilized and additionally contains preservatives, stabilizers, wettable powders or emulsifiers, salts and/or buffers for the regulation of osmotic pressure, and other therapeutically useful materials, and the composition can be formulated by the conventional mixing, granulating or coating method.
  • the formulations for oral administration are exemplified by tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, syrups, granules, and elixirs, etc.
  • These formulations can include diluents (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine) and lubricants (for example, silica, talc, stearate and its magnesium or calcium salt, and/or polyethylene glycol) in addition to the active ingredient.
  • Tablets can include binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone, and if necessary disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavors, and sweeteners can be additionally included thereto.
  • binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone
  • disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavors, and sweeteners can be additionally included thereto.
  • the present invention provides a health functional food comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or amelioration of metabolic disorder, cancer, digestive or circulatory system disorders.
  • the metabolic disorder can be any one selected from the group consisting of obesity, diabetes mellitus, hyperlipidemia, arteriosclerosis, fatty liver, (nonalcoholic) fatty liver cirrhosis, (nonalcoholic) steatohepatitis, liver cirrhosis, celiac disease and hypertension.
  • the cancer can be any one selected from the group consisting of colorectal cancer, breast cancer, ovarian cancer, carcinoid tumor and hepatocellular carcinoma.
  • the digestive or circulatory system disorder can be any one selected from the group consisting of hepatitis, enteritis, colitis, ulcerative enteritis, Crohn's disease, pheochromocytoma, irritable bowel syndrome, gastrointestinal bleeding, peptic ulcer, gastritis, inflammatory bowel disorder, pulmonary syndrome and pulmonary hypertension.
  • the compound represented by formula 1 according to the present invention can be used as a food additive.
  • the compound can be added as it is or as mixed with other food components according to the conventional method.
  • the mixing ratio of active ingredients can be regulated according to the purpose of use (prevention or amelioration).
  • the compound is added preferably by 0.1-90 weight part.
  • the content can be lower than the above but higher content can be accepted as well since the compound has been proved to be very safe.
  • the health beverages containing the composition of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages.
  • the natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xilytole, sorbitol and erythritol.
  • the composition for health beverages of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages in addition to the compound.
  • the natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xilytole, sorbitol and erythritol.
  • natural sweetening agents thaumatin, stevia extract, for example rebaudioside A, glycyrrhizin, etc.
  • synthetic sweetening agents sacharin, aspartame, etc.
  • the content of the natural carbohydrate is preferably 1-20 g and more preferably 5-12 g in 100 g of the composition of the present invention.
  • the compound represented by formula 1 of the present invention can include in variety of nutrients, vitamins, minerals (electrolytes), flavors including natural flavors and synthetic flavors, coloring agents and extenders (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acid, protective colloidal viscosifiers, pH regulators, stabilizers, antiseptics, glycerin, alcohols, carbonators which used to be added to soda, etc.
  • the compound represented by formula 1 of the present invention can also include natural fruit juice, fruit beverages and fruit flesh addable to vegetable beverages.
  • the present invention provides a method for preventing or treating metabolic disorder, cancer, digestive or circulatory system disorders, which comprises the step of administering a pharmaceutical composition or a health functional food comprising a compound represented by formula 1, an optical isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
  • the present invention provides a use of the pharmaceutical composition or the health functional food comprising a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating metabolic disorder, cancer, digestive or circulatory system disorders.
  • tryptophan hydroxylase used in the present invention means an enzyme involved in the synthesis of serotonin.
  • the tryptophan hydroxylase hydroxylates tryptophan to produce 5-hydroxytryptophan.
  • ethyl L-tyrosinate hydrochloride was dissolved in 100 ml of methanol and 800 ml of DCM with vigorous stirring.
  • a solution of triethylamine (154 ml, 1.1 mol) and di-tert-butyl dicarbonate (120.5 g, 0.552 mol) in 200 ml of DCM was added sequentially at 0°C.
  • the resulting suspension was stirred overnight at room temperature. Then, the suspension was filtered to remove solids and the filtrate was washed with water.
  • the organic phase was dried over Na 2 SO 4 and concentrated in vacuo to give ethyl (tert-butoxycarbonyl) -L-tyrosinate (136 g, 80%) as a white solid.
  • Triflic anhydride (25.1 ml, 0.149 mol) was added dropwise to 500 ml of DCM containing the ethyl (tert-butoxycarbonyl)-L-tyrosinate(44 g, 0.142 mol) prepared in Preparative Example 1 and pyridine (44.8 ml, 0.569 mol) at 0 °C .
  • the temperature of the mixture was warmed to ambient temperature and then the mixture was stirred for 1 hour.
  • the mixture was poured into a saturated bicarbonate solution and extracted with DCM.
  • the organic phase of the extract was washed with brine and then dried over anhydrous Na 2 SO 4 .
  • the solvent was removed under reduced pressure, and the concentrate was purified with silica gel.
  • a solution containing Lithium diisopropylamide solution 2.0 M in THF/heptane/ethylbenzene(23.7 ml, 47.5 mmol) in 100 ml of THF was cooled at - 78°C under dry nitrogen atmosphere. While maintaining the temperature at -78 °C, a solution containing ethyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-oxocyclohexyl)propanoate (11.45 g, 36.54 mmol) in 110 ml of anhydrous THF was added dropwise to the cooled solution. The mixture was stirred for 1 hour.
  • Triethyl amine (4.5 g, 44.57 mmol) was added to a solution containing the tert-butyl 2-[bis(tert-butoxycarbonyl)amino]-4-chloro-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate (1.9 g, 4.05 mmol) obtained above in 14 ml of methanol at room temperature.
  • the mixture was stirred at 60 °C for 5 hours and concentrated. Then, the concentrated mixture was purified by column chromatography.
  • di-tert-butyl (4-chloro-7H-pyrrolo[2,3-d]pyrimidine-2-yl)-imidodicarbonate (1.3 g, 87%) was obtained as a white solid.
  • Examples 57 and 70 were prepared by performing the method similar to the preparation method of Example 28.
  • the compound of Example 120 was prepared by performing the method similar to the preparation method of Example 29.
  • the mixture was acidified to pH 4 with 1 N hydrochloric acid. 100 ml of water was additionally added to the mixture, which was extracted three times with EtOAc (50 ml). The mixed organic layer of the extract was washed with brine, dried over sodium sulfate and concentrated. The concentrate was purified by column chromatography.
  • the compounds of Examples 53, 59, 86 and 96 were prepared by performing steps 1 and 2 in the preparation method of Example 31, and the preparation method of Example 28, followed by performing the preparation method of Example 29.
  • the compound of Example 44 was prepared by performing the method similar to the preparation method of Example 31, without performing step 4.
  • the mixture was concentrated, and the concentrate was dissolved in water.
  • the pH of the dissolved concentrate was adjusted to 8 with ammonia water, followed by extracting with ethyl acetate.
  • the organic layer of the extract was dried over anhydrous sodium sulfate and concentrated in vacuo.
  • the concentrate was purified by silica gel column chromatography.
  • the compounds of Examples 118 and 119 were prepared by performing steps 1 to 3 in the preparation method of Example 79, and the preparation method of Example 28, followed by performing the preparation method of Example 29.
  • Examples 89 and 95 were prepared by performing the method similar to the preparation method of Example 80.
  • Methyl 3-amino-2-thiophene carboxylate (2 g, 12.73 mmol) and urea (4.6 g, 76.34 mmol) were heated at 190°C for 4 hours in a sealed tube.
  • the heated reaction mixture was poured into sodium hydroxide solution and the insoluble materials were removed by filtration.
  • the mixture was acidified with hydrochloric acid (HCl, 2N) and the resulting cream-colored precipitate was combined by filtration and dried with air.
  • HCl, 2N hydrochloric acid
  • Triethylamine (94 mg, 0.929 mmol) and (4-methoxyphenyl) methanamine (95.59 mg, 0.697 mmol) were added to (R)-7-bromo-2-chloro-4-(1-(4-chloro-2-(3-methyl-1H-pyrazole-1-yl)phenyl)-2,2,2-trifluoroethoxy)thieno[3,2-d]pyrimidine (250 mg, 0.465 mmol) in ethanol (10 mL). The reaction mixture was reacted at 150°C 1 hour in a single-mode microwave instrument (Biotage Initiator 2.5). The reaction mixture was evaporated and the concentrate was purified by silica gel column chromatography.
  • Examples 105 and 106 were prepared by performing the method similar to the preparation method of Example 91.
  • Table 1 shows the chemical structures and names of the compounds of Examples 1 to 43.
  • Example Chemical Formula Compound Name 1 (S)-2-amino-3-(4-((7-((5-fluoro-[1,1'-biphenyl]-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl)oxy)phenyl)propionic acid hydrochloride 2 (S)-2-amino-3-(4-((7-(3-bromobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl)oxy)phenyl)propionic acid hydrochloride 3 (S)-2-amino-3-(4-((2-amino-7-(2-bromo-4-fluorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl)oxy)phenyl)propionic acid hydrochloride 4 (S)-2-amino-3-(4-((2-amin
  • Table 2 shows the chemical structures and names of the compounds of Examples 44 to 120.
  • Example Chemical Formula Compound Name 44 (2 S)-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazole-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimid ine-4-yl)cyclohex-3-ene-1-yl)-2-((tert-butoxycarbonyl)amino)pr opionic acid 45
  • the compounds of Examples 1 to 120 according to the present invention were analyzed by nuclear magnetic resonance spectroscopy (NMR) or liquid chromatography-mass spectrometry (LC-MS).
  • NMR nuclear magnetic resonance spectroscopy
  • LC-MS liquid chromatography-mass spectrometry
  • Table 3 shows the NMR or LCMS values of the compounds of Examples 1 to 43.
  • Table 4 shows the NMR or LCMS values of the compounds of Examples 44 to 120.
  • TPH1 tryptophan hydroxylase 1
  • BPS Bioscience Catalog # 72053
  • the TPH1 inhibitor screening assay kit was used according to the manufacturer's manual. The results are shown in table 5 below.
  • the synthesized compound was dissolved in DMSO, which was added to a 96-well microplate (10 ⁇ l/well), to which TPH1 enzyme was added (40 ⁇ l/well). Then, TPH1 reaction solution was added to the microplate (50 ⁇ l/well) and the microplate was shaded with aluminum foil. The microplate was transferred to 4°C environment, shaken carefully and incubated for 4 hours. After adding a quench solution to the microplate (10 ⁇ l/well) , the TPH1 activity was measured by reading the degree of fluorescence color development with a Flexstation3 microplate reader. At this time, the excitation spectrum was 300 nm and the emission spectrum was 360 nm.
  • the compounds of examples according to the present invention showed low IC 50 values of ⁇ M level, indicating that the inhibitory effect of the compounds on TPH1 was excellent even at low concentrations. Specifically, most of the example compounds exhibited IC 50 values of 1 ⁇ M or less, and in particular, the compounds of Examples 8, 45 and 67 showed IC 50 values of nM level (36 nM, 98 nM and 91 nM, respectively), indicating that the inhibitory effect of the compounds on TPH1 was excellent even at significantly low concentrations.
  • the compound represented by formula 1 according to the present invention had an excellent inhibitory effect on TPH1, so that the compound can be effectively used for the prevention or treatment of metabolic disorder, cancer, digestive or circulatory system disorders, which are the diseases related to TPH1 activity.
  • the efficacy in the inflammatory bowel disorder animal model was evaluated.
  • the compound of Example 53 according to the present invention was used, and as a comparative example, LX1606 ((2S)-2-Amino-3-[4-[2-amino-6-[[(1R)-1-[4-chloro-2-(3-methylpyrazo1-1-yl)phenyl]-2,2,2-trifluoroethyl]oxy]pyrimidin-4-yl]phenyl]propionic acid ethyl ester), well known as a THF inhibitor, was used.
  • the specific experimental methods are as follows.
  • Example 53 and LX1606 were dissolved in 0.25% methylcellulose (MC) solution, which was orally administered to mice at the dose of 100 and 300 mg/kg/time using a 1 mL syringe.
  • the compound of Example 53 and LX1606 were administered for 7 days, starting one day prior to dextran sulfate sodium (DSS) administration. Before and after the administration, the samples of colon tissue were collected from each mouse treated with the compound of Example 53 or the control drug (LX1606) to confirm clinical symptoms.
  • MC methylcellulose
  • Enteritis was induced in mice by freely drinking 2.5% DSS (molecular weight: 36,000-50,000 M.Wt; manufactured by MP Biomedicals, Canada) aqueous solution for 6 days, and the body weight, stiffness of the stool, and the presence or absence of bloody stool were observed daily from the start of the administration.
  • DSS molecular weight: 36,000-50,000 M.Wt; manufactured by MP Biomedicals, Canada
  • MPO myeloperoxidase activity measurement
  • colon tissues were collected and stored at -80°C until immediately before use.
  • the severity of colitis was evaluated by colon length and histological examination 6 days after the start of DSS administration and 5 days after recovery.
  • Figure 1 shows images of the collected colon tissues
  • Figure 2 shows a graph illustrating the colon length for each experimental group.
  • DAI Disease activity index
  • DAI was measured for all 5 days of DSS treatment and 5 days of recovery. Visual scores were assessed using the scoring system described in the table for DSS colitis.
  • Colon permeability was measured to confirm if the compound of the present invention affected the amelioration of inflammatory bowel disorder.
  • the intestinal epithelial layer acts as a barrier to pathogens and ingested toxins present in the intestinal lumen.
  • the importance of the intestinal epithelial layer was measured by the changes in intercellular permeability and intimate junction function observed in inflammatory bowel disease (IBD) and colorectal cancer.
  • FITC-dextran 4kDa (10 mg/20 g) was administered 4 hours before sacrifice on the last day, serum was isolated from blood (300-800 mL) and the fluorescence value was measured at ex 485 and em 528. The results are shown in Figure 4 .
  • the tissue sample was fixed in blue so that the purple of hematoxylin did not overlap with the red of eosin.
  • the tissue sample was treated with 90% ethanol and stained with eosin, and soaked in running water and 70/80/90/100% ethanol for dehydration. Finally, xylene was treated for clearing, and then the slides were dried and mounted, followed by tissue microscopy to observe the changes of crypt architecture, cell infiltration, goblet cell depletion and crypt abscess. The results are shown in Table 5.
  • Example 53 From the results of Experimental Example 3, the compound of Example 53 according to the present invention was confirmed to have an excellent therapeutic effect on inflammatory bowel disorder. Therefore, the compound represented by formula 1 according to the present invention can be effectively used for the treatment of inflammatory bowel disorder.
  • Powders were prepared by mixing all the above components, which were filled in airtight packs according to the conventional method for preparing powders.
  • Tablets were prepared by mixing all the above components by the conventional method for preparing tablets.
  • Capsules were prepared by mixing all the above components, which were filled in gelatin capsules according to the conventional method for preparing capsules.
  • Injectable solutions were prepared by incorporating all the above components in the prescribed amounts according to the conventional method for preparing injectable solutions.
  • Vitamin complex proper amount Vitamin A acetate 70 mg Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 mg Vitamin C 10 mg Biotin 10 mg Nicotinic acid amide 1.7 mg Folic acid 50 mg Calcium pantothenate 0.5 mg Minerals proper amount Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium phosphate monobasic 15 mg Potassium phosphate dibasic 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg
  • Vitamins and minerals were mixed according to the preferable composition rate for health functional food. However, the composition rate can be adjusted.
  • the constituents were mixed according to the conventional method for preparing health functional food and then the composition for health functional food was prepared according to the conventional method.
  • the above constituents were mixed according to the conventional method for preparing health beverages.
  • the mixture was heated at 85°C for 1 hour with stirring and then filtered.
  • the filtrate was loaded in sterilized containers, which were sealed and sterilized again, stored in a refrigerator until they would be used for the preparation of a composition for health beverages.
  • the constituents appropriate for favorite beverages were mixed according to the preferred mixing ratio but the composition ratio can be adjusted according to regional and national preferences, etc.
  • novel tryptophan hydroxylase inhibitor of the present invention can be effectively used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or circulatory system disorders, related to TPH1 activity.
  • disorders such as metabolic disorders, cancer, digestive or circulatory system disorders, related to TPH1 activity.
  • the novel tryptophan hydroxylase inhibitor can be effectively used for the treatment of inflammatory bowel disorder.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

  1. Composé représenté par la formule 1 ci-dessous, un isomère optique de celui-ci, un solvate de celui-ci, un hydrate de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci
    Figure imgb0298
     dans lequel,
    R1 est un hydrogène ou un alkyle en C1-10 ;
    Figure imgb0299
     contenant R2 peut former
    Figure imgb0300
     ou
    Figure imgb0301
    R6 est un hydrogène ou un tert-butoxycarbonyle;
    R3 est
    Figure imgb0302
    Figure imgb0303
    R7a, R7b, R7c et R7d sont indépendamment un atome d'hydrogène, un NH2 ou un groupe méthyle ; R4 est un atome d'hydrogène, un groupe cycloalkyle en C3-10, un groupe aryle en C6-10 ou un groupe hétérocycloalkyle de 3 à 10 membres ou un groupe hétéroaryle de 5 à 13 membres
    L1 est
    Figure imgb0304
     L2 est -(CH2)x-, -(CH2)y-O-, -(CH2)z-N(Ra)-, -CH(C(Rb)3)-O- ou
    Figure imgb0305
     dans lequel x est un nombre entier de 0 à 4, y est un nombre entier de 0 à 4, z est un nombre entier de 0 à 4, et Ra est un hydrogène ou un alkyle en C1-6, Rb est un hydrogène ou un halogène ;
    dans lequel lesdits groupes alkyle, aryle, cycloalkyle, hétérocycloalkyle et hétéroaryle peuvent être indépendamment substitués par un ou plusieurs substituants choisis dans le groupe constitué par les halogènes ; NH2 ; hydroxy ; alkyle en C1-6 ; alcoxy en C1-6 ; aryle en C6-10 ; hydroxyle alkyle en C1-6 ; hydroxyle alcoxy en C1-6 ; hydroxyle aryle en C6-10 ; halogéno alkyle en C1-6 ; halogéno alcoxy en C1-6 ; halogéno aryle en C6-10 ; alkyle en C1-6 aryle en C6-10 ; alcoxy en C1-6 aryle en C6-10 ; alkylcarbonyle en C1-6 ; alcoxycarbonyle en C1-6 ; halogéno cycloalcényle en C3-10 ; halogéno alcoxy en C1-6 aryle en C6-10 ; cycloalkyle en C3-10 ; alcoxy en C1-6 aryle en C6-10 ; hydroxyle alkyle en C1-6 aryle en C6-10 ; hétéroaryle à 5-13 chaînons ; cycles condensés contenant halophényle, pyridine et cycloalkyle en C5-7 ; alkyle en C1-6 hétéroaryle de 5 à 13 chaînons; hétérocycloalcényle de 3 à 10 chaînons; et alkyle en C1-6 hétérocycloalcényle de 3 à 10 chaînons, et le substituant peut être lié à l'alkyle, l'aryle, le cycloalkyle, l'hétérocycloalkyle ou l'hétéroaryle par des liaisons simples ou des doubles liaisons ;
    lesdits hétéroaryle, hétérocycloalkyle, hétérocycloalcényle comprennent indépendamment un ou plusieurs hétéroatomes choisis dans le groupe constitué de N, O et S ; et
    l'alkyle ou l'alcoxy peuvent avoir une forme linéaire ou ramifiée.
  2. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel :
    R1 est un hydrogène ou un alkyle en C1-6 ;
    R4 est un hydrogène, un aryle en C6-10 ou un hétérocycloalkyle à 5-6 chaînons ou un hétéroaryle à 5-6 chaînons;
    L2 est -(CH2)x-, -(CH2)y-O-, -(CH2)z-N(Ra)-,
    Figure imgb0306
     ou
    Figure imgb0307
     dans lequel x est 0 ou 1, y est 0 ou 1, z est 0 ou 1, et Ra est un hydrogène ou un alkyle en C1-6 ;
    dans lequel lesdits groupes alkyle, aryle, cycloalkyle, hétérocycloalkyle et hétéroaryle peuvent être indépendamment substitués par un ou plusieurs substituants choisis dans le groupe constitué par les halogènes, NH2, les groupes hydroxy, alkyle en C1-4, alcoxy en C1-4, phényle, hydroxyle alkyle en C1-4, hydroxyle alcoxy en C1-4, hydroxyphényle, halogèno, alkyle en C1-4, halogéno alcoxy en C1-4, halogénophényle, alkylphényle en C1-4, alcoxyphényle en C1-4, alkylcarbonyle en C1-4, alcoxycarbonyle en C1-4 ; halogéno cycloalcényle en C5-6 ; halogéno alcoxyphényle en C1-4 ; cycloalkyle en C3-6 alcoxyphényle en C1-4 ; hydroxyle alkylphényle en C1-4 ;
    hétéroaryle à 5-9 chaînons ; cycles fusionnés contenant un halogénophényle, une pyridine et un cycloheptyle ; alkyle en C1-4 hétéroaryle à 5-9 chaînons ; hétérocycloalcényle à 5-6 chaînons ; et alkyle en C1-6 hétérocycloalcényle à 5-9 chaînons, et le substituant peut être lié à un alkyle, un aryle, un cycloalkyle, un hétérocycloalkyle ou un hétéroaryle par des liaisons simples ou des doubles liaisons ;
    dans lequel lesdits hétéroaryle, hétérocycloalkyle et hétérocycloalcényle comprennent indépendamment un ou plusieurs hétéroatomes choisis dans le groupe constitué de N, O et S ; et l'alkyle ou l'alcoxy peuvent avoir une forme linéaire ou ramifiée.
  3. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel :
    R1 est un hydrogène ou un alkyle en C1-5 ;
    R4 est un hydrogène,
    Figure imgb0308
     ou
    Figure imgb0309
    R8a et R8b sont indépendamment un atome d'hydrogène, un atome d'halogène, un groupe alcoxy en C1-4, un groupe phényle, un groupe furane, un groupe benzofurane, un groupe pyrazole substitué par un groupe méthyle, un groupe dihydropyrane, un groupe tétraméthyldihydropyrane, un groupe cyclohexényle ou un groupe difluorocyclohexényle, et le groupe phényle peut être substitué par un substituant choisi dans le groupe constitué par un atome d'halogène, un groupe hydroxy, un groupe alcoxy en C1-4, un groupe halogénoalcoxy en C1-4, un groupe cycloalkyle en C3-6 alcoxy en C1-4 et un groupe hydroxyalkyle en C1-4,
    R8c est un alcoxycarbonyle en C1-4,
    R8d est
    Figure imgb0310
    L2 est
    Figure imgb0311
    Figure imgb0312
     et
    les groupes alkyle ou alcoxy peuvent avoir une forme linéaire ou ramifiée.
  4. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel R1 est un atome d'hydrogène, un groupe méthyle, éthyle, n-butyle, t-butyle, i-butyle, n-pentyle, t-pentyle, i-pentyle ou néo-pentyle.
  5. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1,
    dans lequel R3 est
    Figure imgb0313
    Figure imgb0314
    Figure imgb0315
  6. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel :
    R4 est un hydrogène,
    Figure imgb0316
     ou
    Figure imgb0317
    dans lequel, R8a est un hydrogène, halogène, un groupe alcoxy en C1-4
    Figure imgb0318
    Figure imgb0319
    R8b est un hydrogène, halogène,
    Figure imgb0320
    Figure imgb0321
    Figure imgb0322
    Figure imgb0323
    R8c est un isopropoxycarbonyle, et
    R8d est
    Figure imgb0324
  7. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel :
    L2 est
    Figure imgb0325
    Figure imgb0326
  8. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel :
    R4 est un hydrogène,
    Figure imgb0327
    Figure imgb0328
    Figure imgb0329
    Figure imgb0330
    Figure imgb0331
    Figure imgb0332
    Figure imgb0333
    Figure imgb0334
    Figure imgb0335
    Figure imgb0336
     ou
    Figure imgb0337
  9. Composé, son isomère optique, son solvate, son hydrate ou son sel pharmaceutiquement acceptable selon la revendication 1, dans lequel le composé représenté par la formule 1 est choisi dans le groupe constitué par les composés suivants :
    <30> le chlorhydrate d'acide (2S)-2-amino-3-(4-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)thiéno[3,2-d]pyrimidine-7-yl) cyclohex-3-ène-1-yl)propionique ;
    <31> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <32> le chlorhydrate d'acide (2S)-2-amino-3-(4-(6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)-2-méthylpyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <33> le chlorhydrate d'acide (2S)-2-amino-3-(4-(7-((3'-méthoxy-[1,1'-biphényl]-4-yl)méthyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <34> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-méthoxy-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <35> le chlorhydrate d'acide (2S)-2-amino-3-(4-(4-((R)-2,2,2-trifluoro-1-(3'-méthoxy-[1,1'-biphényl]-4-yl)éthoxy)thiéno[3,2-d]pyrimidine-7-yl)cyclohex-3-ène-1-yl)propionique ;
    <36> le (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionate d'éthyle ;
    <44> l'acide (2S)-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)-2-((tert-butoxycarbonyl)amino)propionique ;
    <45> l'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <46> le chlorhydrate d'acide (2S)-2-amino-3-(4-(1-(5-chloro-4'-fluoro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)thiéno[3,2-d]pyrimidine-7-yl)phényl)propionique ;
    <47> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-(1-(5-chloro-4'-fluoro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <48> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-(1-(5-chloro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <49> le chlorhydrate d'acide (2S)-2-amino-3-(4-(1-((3'-méthoxy-[1,1'-biphényl]-4-yl)méthyl)-1H-pyrazole-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <50> le chlorhydrate d'acide (2S)-2-amino-3-(4-(4-(1-(5-chloro-4'-fluoro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)thiéno[3,2-d]pyrimidine-7-yl) cyclohex-3-ène-1-yl)propionique ;
    <51> le chlorhydrate d'acide (2S)-2-amino-3-(4-(1-(5-chloro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)thiéno[3,2-d]pyrimidine-7-yl)cyclohex-3-ène-1-yl)propionique ;
    <52> le dichlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-(4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridine-11-ylidène)-pipéridine-1-yl)-cyclohex-3-ène-1-yl)propionique ;
    <53> l'hippurate de (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionate d'éthyle ;
    <54> le dihydrochlorure d'acide (2S)-2-amino-3-(4-(5-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyridine-3-yl)cyclohex-3-ène-1-yl)propionique ;
    <55> le chlorhydrate d'acide (2S)-2-amino-3-(4-(8-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)imidazo[1,2-a]pyrazine-3-yl)cyclohex-3-ène-1-yl)propionique ;
    <57> l'acide (2S)-2-amino-3-(4-(4-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)thièno[3,2-d]pyrimidine-7-yl)cyclohex-3-ène-1-yl)propionique ;
    <58> l'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-méthoxy-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)cyclohex-3-ène-l-yl)propionique;
    <59> l'hippurate de (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionate de méthyle ;
    <60> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-(2,2,2-trifluoroéthoxy)-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <61> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(3'-(cyclopropylméthoxy)-[1,1'-biphényl]-4-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <62> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-butoxy-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique;
    <63> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(3'-éthoxy-[1,1'-biphényl]-4-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <64> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(1-méthyl-1H-pyrazole-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <65> le (2S)-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)-2-((tert-butoxycarbonyl)amino)propionate d'éthyle ;
    <66> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <67> l'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidine-4-yl)cyclohex-3-ene-1-yl)propionique ;
    <68> l'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(1-méthyl-1H-pyrazole-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <71> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(2-(benzofuran-3-yl)-4-chlorophényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <74> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(furan-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <75> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(5-chloro-4',4'difluoro-2',3' ,4',5'-tétrahydro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <76> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(5-chloro-4'-méthoxy-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <77> le Chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(2,2,6,6-tétraméthyl-3,6-dihydro-2H-pyran-4-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <79> le chlorhydrate d'acide 8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <80> l'acide 8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <82> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3,6-dihydro-2H-pyran-4-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <83> le chlorhydrate d'acide 8-(2-amino-6-((R)-1-(4-chloro-2-(3,6-dihydro-2H-pyran-4-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <84> le chlorhydrate d'acide 8-(4-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)thiéno[3,2-d]pyrimidine-7-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <85> l'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3,6-dihydro-2H-pyran-4-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <86> l'hippurate de (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionate d'éthyle ;
    <87> le chlorhydrate d'acide 8-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-méthoxy-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <88> le chlorhydrate d'acide 8-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <89> l'acide 8-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-méthoxy-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <90> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphényl]-4 - yl)éthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <92> l'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)cyclohex-3-ène-l-yl)propionique;
    <93> le chlorhydrate d'acide 8-(4-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)thieno[3,2-d]pyrimidine-7-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <94> le chlorhydrate d'acide 8-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <95> l'acide 8-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphényl]-4-yl)éthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <96> l'hippurate de (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionate de néopentyle ;
    <97> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3,4-dihydro-2H-pyran-5-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <98> le chlorhydrate d'acide (2S)-2-amino-3-(4-(2-amino-6-((R)-1-(5-chloro-2',3',4',5'-tétrahydro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <99> le chlorhydrate d'acide (S)-2-amino-3-((R)-4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <100> le chlorhydrate d'acide (S)-2-amino-3-((S)-4-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <101> le chlorhydrate d'acide (S)-2-amino-3-((R)-4-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <102> le chlorhydrate d'acide (S)-2-amino-3-((S)-4-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)cyclohex-3-ène-1-yl)propionique ;
    <107> le chlorhydrate d'acide 8-(2-amino-4-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)thieno[3,2-d]pyrimidine-7-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <108> le chlorhydrate d'acide 8-(2-amino-6-((R)-1-(4-chloro-2-(3,4-dihydro-2H-pyran-5-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <109> le chlorhydrate d'acide 8-(2-amino-6-((R)-1-(5-chloro-2',3',4',5'-tétrahydro-[1,1'-biphényl]-2-yl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <110> le chlorhydrate d'acide (3S,5R)-8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <111> le chlorhydrate d'acide (3S,5S)-8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <112> le chlorhydrate d'acide (3R,5R)-8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <113> le chlorhydrate d'acide (3R,5S)-8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <114> le chlorhydrate d'acide (3S,5R)-8-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <115> le chlorhydrate d'acide (3S,5S)-8-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <116> le chlorhydrate d'acide (3R,5R)-8-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <117> le chlorhydrate d'acide (3R,5S)-8-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylique ;
    <118> l'hippurate d'éthyl 8-(2-amino-6-((R)-1-(4-chloro-2-(5,6-dihydro-2H-pyran-3-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylate;
    <119> l'hippurate d'éthyl 8-(2-amino-6-((R)-1-(4-chloro-2-(3-méthyl-1H-pyrazole-1-yl)phényl)-2,2,2-trifluoroéthoxy)pyrimidine-4-yl)-2-azaspiro[4.5]dec-7-ène-3-carboxylate.
  10. Composition pharmaceutique comprenant le composé de la revendication 1, un isomère optique de celui-ci, un solvate de celui-ci, un hydrate de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci comme ingrédient actif pour une utilisation dans la prévention ou le traitement d'un trouble métabolique.
  11. Composition pharmaceutique à utiliser selon la revendication 10, dans laquelle le trouble métabolique est l'un quelconque choisi dans le groupe constitué par l'obésité, le diabète sucré, l'hyperlipidémie, l'artériosclérose, la stéatose hépatique, stéatose hépatique cirrhose (non alcoolique), la stéatose hépatite (non alcoolique), la cirrhose du foie, la maladie cœliaque et l'hypertension.
  12. Composition pharmaceutique comprenant le composé de la revendication 1, un isomère optique de celui-ci, un solvate de celui-ci, un hydrate de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci comme ingrédient actif pour une utilisation dans la prévention ou le traitement du cancer.
  13. Composition pharmaceutique à utiliser selon la revendication 12, dans laquelle le cancer est l'un quelconque choisi dans le groupe constitué par le cancer colorectal, le cancer du sein, le cancer ovarien, la tumeur carcinoïde et le carcinome hépatocellulaire.
  14. Composition pharmaceutique comprenant le composé de la revendication 1, un isomère optique de celui-ci, un solvate de celui-ci, un hydrate de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci comme ingrédient actif pour une utilisation dans la prévention ou le traitement d'un trouble du système digestif ou circulatoire.
  15. Composition pharmaceutique à utiliser selon la revendication 14, dans laquelle le trouble du système digestif ou circulatoire est l'un quelconque choisi dans le groupe constitué par l'hépatite, le syndrome pulmonaire, l'hypertension pulmonaire et le trouble intestinal inflammatoire choisi dans le groupe constitué par l'entérite, la colite, l'entérite ulcérative, la maladie de Crohn, le phéochromocytome, le syndrome du côlon irritable, l'hémorragie gastro-intestinale, l'ulcère gastroduodénal et la gastrite.
EP18848270.7A 2017-08-24 2018-08-24 Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant Not-in-force EP3674303B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170106983 2017-08-24
PCT/KR2018/009796 WO2019039905A1 (fr) 2017-08-24 2018-08-24 Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant

Publications (3)

Publication Number Publication Date
EP3674303A1 EP3674303A1 (fr) 2020-07-01
EP3674303A4 EP3674303A4 (fr) 2021-05-05
EP3674303B1 true EP3674303B1 (fr) 2022-07-20

Family

ID=65439133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18848270.7A Not-in-force EP3674303B1 (fr) 2017-08-24 2018-08-24 Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant

Country Status (5)

Country Link
US (1) US11407763B2 (fr)
EP (1) EP3674303B1 (fr)
KR (1) KR102087907B1 (fr)
CN (1) CN111315746B (fr)
WO (1) WO2019039905A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022149925A1 (fr) * 2021-01-08 2022-07-14 광주과학기술원 Nouvel inhibiteur de tryptophane hydroxylase et son utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2684821T3 (es) * 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
BRPI0814105A2 (pt) * 2007-07-11 2015-02-03 Lexicon Pharmaceuticals Inc Métodos e composições para o tratamento de hipertensão pulmonar e doenças e distúrbios relacionados
US8691429B2 (en) 2008-10-14 2014-04-08 Samsung Sdi Co., Ltd. Polymer battery pack and method for manufacturing the same
CN102711749A (zh) * 2009-11-05 2012-10-03 莱西肯医药有限公司 用于癌症治疗的色氨酸羟化酶抑制剂
WO2012058598A1 (fr) * 2010-10-29 2012-05-03 The Trustees Of Columbia University In The City Of New York Procédés de prévention et de traitement de l'hyperlipidémie ou de l'athérosclérose
WO2014082034A1 (fr) * 2012-11-26 2014-05-30 Lexicon Pharmaceuticals, Inc. Procédés de traitement du syndrome du côlon irritable
JP2016509017A (ja) * 2013-02-15 2016-03-24 マクマスター ユニバーシティー 肥満の治療方法
KR101781600B1 (ko) 2015-06-30 2017-09-25 한양대학교 산학협력단 항암 및 항염증 활성을 갖는 약물 복합체
CA3047212A1 (fr) * 2017-01-30 2018-08-02 Chiesi Farmaceutici S.P.A. Derives de tyrosine amide utilises en tant qu'inhibiteurs de la rho-kinase

Also Published As

Publication number Publication date
US20210155634A1 (en) 2021-05-27
EP3674303A1 (fr) 2020-07-01
KR20190022416A (ko) 2019-03-06
US11407763B2 (en) 2022-08-09
CN111315746A (zh) 2020-06-19
KR102087907B1 (ko) 2020-03-11
CN111315746B (zh) 2022-11-29
EP3674303A4 (fr) 2021-05-05
WO2019039905A1 (fr) 2019-02-28

Similar Documents

Publication Publication Date Title
EP3325481B1 (fr) Composés utiles pour traiter des troubles associés à kit et pdgfr
KR101880280B1 (ko) 키나제 억제제로서의 퀴놀린 및 퀴녹살린 유도체
CN101723936B (zh) 激酶抑制剂及其在药学中的用途
TWI542590B (zh) １，２-雙取代雜環化合物
WO2018166493A1 (fr) Dérivé d&#39;hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales
US11040979B2 (en) Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN114846005A (zh) Shp2抑制剂及其应用
EP3381896A1 (fr) Nouveau composé de biphényle ou un sel de celui-ci
CN110872289A (zh) 作为IDO1和/或TDO抑制剂的新颖的8-取代的咪唑并[1,5-a]吡啶
EP3162801B1 (fr) Sel d&#39;un composé hétérocyclique substitué par un groupe halogène
JP2003528095A (ja) ＧＳＫ３．β阻害剤としての２−アミノ−３−（アルキル）−ピリミドン誘導体
CN115279749A (zh) Shp2抑制剂及其组合物和应用
EP3697786B1 (fr) Pyrrolopyridines substituées utilisées en tant qu&#39;inhibiteurs de la kinase apparentée au récepteur de l&#39;activine
WO2023131277A1 (fr) Inhibiteur de l&#39;inflammasome nlrp3 et utilisations associées
US11236083B2 (en) Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
WO2023232069A1 (fr) Dérivé d&#39;azaquinolinone, son procédé de préparation et son utilisation
WO2020215998A1 (fr) Composé hétérocyclique à cinq chaînons à base de pyrimido et son utilisation en tant qu&#39;inhibiteur d&#39;idh2 mutant
EP3674303B1 (fr) Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant
CN117402185A (zh) 三嗪类化合物及其在药物中的应用
JP2021535924A (ja) 新規なチアゾール誘導体及びその薬学的に許容される塩
JP2021533085A (ja) タンキラーゼ阻害剤としての１，２，４−トリアゾール誘導体
CN111247143B (zh) 可用作蛋白激酶抑制剂的吡啶并喹唑啉衍生物
TW202132313A (zh) 咪唑烷酮類化合物、包含其的醫藥組合物及其應用
WO2016034634A1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak
CN114671878B (zh) 取代的含氮双环化合物及其用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210408

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 487/04 20060101AFI20210331BHEP

Ipc: A61K 31/519 20060101ALI20210331BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211007

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220310

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018038276

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1505501

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220824

Year of fee payment: 5

Ref country code: DE

Payment date: 20220818

Year of fee payment: 5

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20220720

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220822

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221121

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221020

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1505501

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221120

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221021

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018038276

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220824

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220831

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

26N No opposition filed

Effective date: 20230421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602018038276

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230824

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240301

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220720